Renalytix PLC Result of General Meeting
01 November 2024 - 1:10AM
RNS Regulatory News
RNS Number : 4622K
Renalytix PLC
31 October 2024
Renalytix
plc
("Renalytix" or the
"Company")
Result of General
Meeting
LONDON and NEW YORK, 31 October 2024
- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an
artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to
drive improved patient outcomes and advance value-based care,
announces that, at the General Meeting ("GM") held earlier today, all
resolutions were passed. Further details of each
of the resolutions are set out in
the Circular that contains the
Notice of General Meeting, which was sent to the Company's
shareholders on 11 October 2024.
The results of the GM are detailed
below:
|
|
In favour
|
|
|
Against
|
|
|
Withheld
|
|
Resolution
|
Votes
|
%
|
|
Votes
|
%
|
|
Votes
|
|
1
|
101,692,587
|
98.73
|
|
1,311,467
|
1.27
|
|
41,789
|
|
2
|
102,375,306
|
99.85
|
|
157,078
|
0.15
|
|
513,459
|
|
3
|
101,675,617
|
98.71
|
|
1,326,507
|
1.29
|
|
43,719
|
For further information, please
contact:
|
Renalytix Plc
James McCullough, CEO
|
www.renalytix.com
Via Walbrook
PR
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint
Broker)
Nicholas Moore / Nick Harland / Ben
Good
|
Tel: 020 7710
7600
|
|
Oberon Capital (Joint Broker and Sole
Bookrunner)
Mike Seabrook / Nick Lovering /
Jessica Cave
|
Tel: 020 3179
5300
|
|
Walbrook PR Limited
Alice Woodings
|
Tel: 020 7933
8780 or renalytix@walbrookpr.com
Mob: 07407
804 654
|
|
CapComm Partners
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
|
|
| |
The
person responsible for making this Announcement on behalf of the
Company is
James
McCullough, Chief Executive Officer.
About Renalytix plc
Renalytix (LSE: RENX) (OTCQB: RNLXY)
is an artificial intelligence enabled in-vitro diagnostics and
laboratory services company that is the global founder and leader
in the field of bioprognosis™ for kidney health. In late 2023, our
kidneyintelX.dkd test was recognized as the first and only
FDA-authorized prognostic test to enable early-stage CKD (stages
1-3b) risk assessment for progressive decline in kidney function in
T2D patients. By understanding how disease will progress, patients
and clinicians can take action earlier to improve outcomes and
reduce overall health system costs. For more information,
visit www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
ROMWPGBAUUPCGWG
Renalytix (LSE:RENX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From Nov 2023 to Nov 2024
